Stem cells

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2551-2557

  Neofytou, Evgenios ^a   O'Brien, Connor Galen ^a   Couture, Larry A ^b   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CARCINOGENICITY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOGENICITY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; HEALTH CARE FACILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; REGENERATIVE MEDICINE; SAFETY; STANDARDS; TRANSLATIONAL RESEARCH; TRANSPLANTATION; TRENDS; UNITED STATES;

ANIMALS; BIOLOGICAL SPECIMEN BANKS; CELL DIFFERENTIATION; HISTOCOMPATIBILITY TESTING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; SAFETY; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84936791706     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80575     Document Type: Review

References (57)

1. Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: Mechanisms, signaling, and translation. Sci Transl Med. 2014;6(265):265sr6.
2. Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147.
3. Hyun I. The bioethics of stem cell research and therapy. J Clin Invest. 2010;120(1):71-75.
4. Zhan X, et al. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet. 2004;364(9429):163-171.
5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
6. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
7. Matsa E, Burridge PW, Wu JC. Human stem cells for modeling heart disease and for drug discovery. Sci Transl Med. 2014;6(239):239ps6.
8. Scott CT, Magnus D. Wrongful termination: lessons from the geron clinical trial. Stem Cells Transl Med. 2014;3(12):1398-1401.
9. Lebkowski J. GRNOPC1: The world's first embryonic stem cell-derived therapy. Interview with Jane Lebkowski. Regen Med. 2011;6(6 suppl):11-13.
10. Schwartz SD, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509-516.
11. Schwartz SD, et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet. 2012;379(9817):713-720.
12. Cyranoski D. Next-generation stem cells cleared for human trial. Nature News. http://www.nature. com/news/next-generation-stem-cells-clearedfor-human-trial-1.15897. Updated September 12, 2014. Accessed May 5, 2015.
13. [No authors listed]. First stem cell-derived islets in humans. Nat Biotech. 2014;32(10):969.
14. Menasche P, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: A translational experience. Eur Heart J. 2015;36(12):743-750.
15. Garber K. Inducing translation. Nat Biotechnol. 2013;31(6):483-486.
16. Pearl JI, Kean LS, Davis MM, Wu JC. Pluripotent stem cells: immune to the immune system? Sci Transl Med. 2012;4(164):164ps25.
17. Carpenter MK, Frey-Vasconcells J, Rao MS. Developing safe therapies from human pluripotent stem cells. Nat Biotechnol. 2009;27(7):606-613.
18. Feigal EG, Tsokas K, Viswanathan S, Zhang J, Priest C, Pearce J, Mount N. Proceedings: international regulatory considerations on development pathways for cell therapies. Stem Cells Transl Med. 2014;3(8):879-887.
19. Bosse R, Singhofer-Wowra M, Rosenthal F, Schulz G. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells. 1997; 15(suppl 1):275-280.
20. Bosse R, et al. Production of stem-cell transplants according to good manufacturing practice. Ann Hematol. 2000;79(9):469-476.
21. Cao N, et al. Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res. 2013;23(9):1119-1132.
22. Burridge PW, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855-860.
23. Griessinger CM, et al. 64Cu antibody-targeting of the T-cell receptor subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A. 2015;112(4):1161-1166.
24. Nguyen PK, Riegler J, Wu JC. Stem cell imaging: from bench to bedside. Cell Stem Cell. 2014;14(4):431-444.
25. Li Z, et al. Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells. 2008;26(4):864-873.
26. Lee AS, et al. Preclinical derivation and imaging of autologously transplanted canine induced pluripotent stem cells. J Biol Chem. 2011;286(37):32697-32704.
27. Cunningham JJ, Ulbright TM, Pera MF, Looijenga LH. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol. 2012;30(9):849-857.
28. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19(8):998-1004.
29. Toupet K, et al. Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice. Arthritis Rheum. 2013;65(7):1786-1794.
30. Laflamme MA, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25(9):1015-1024.
31. Wiewrodt R, et al. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrugmediated tumor cell killing. Cancer Gene Ther. 2003;10(5):353-364.
32. Kooreman NG, Ransohoff JD, Wu JC. Tracking gene and cell fate for therapeutic gain. Nat Mater. 2014;13(2):106-109.
33. Cao F, et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation. 2006;113(7):1005-1014.
34. Ben-David U, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013;12(2):167-179.
35. Lee MO, et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A. 2013;110(35):E3281-E3290.
36. Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Transl Med. 2013;2(8):607-613.
37. de Almeida PE, Ransohoff JD, Nahid A, Wu JC. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res. 2013;112(3):549-561.
38. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells. 2008;26(1):89-98.
39. Drukker M, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A. 2002;99(15):9864-9869.
40. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212-215.
41. de Almeida PE, et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to selftolerance. Nat Commun. 2014;5:3903.
42. Marx V. Stem cells: disease models that show and tell. Nat Methods. 2015;12(2):111-114.
43. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells. 2007;25(4):983-985.
44. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26(7):739-740.
45. Okita K, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409-412.
46. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366(9502):2019-2025.
47. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLAmatched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11(2):147-152.
48. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines. Stem Cells. 2012;30(2):180-186.
49. Bravery CA. Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense? Stem Cells Dev. 2015;24(1):1-10.
50. Deuse T, et al. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell. 2015;16(1):33-38.
51. Prescott C. The business of exploiting induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci. 2011;366(1575):2323-2328.
52. Liang G, Zhang Y. Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective. Cell Res. 2013;23(1):49-69.
53. Andrews PW, et al. Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol. 2014;32(8):724-726.
54. Thompson SD. Scientific innovation's two Valleys of Death: how blood and tissue banks can help to bridge the gap. Stem Cells Dev. 2014;23(suppl 1):68-72.
55. Trounson A, DeWitt ND, Feigal EG. The Alpha Stem Cell Clinic: A model for evaluating and delivering stem cell-based therapies. Stem Cells Transl Med. 2012;1(1):9-14.
56. Jacquet L, et al. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol Med. 2013;5(1):10-17.
57. Devito L, et al. Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines from a single donor. Stem Cells Transl Med. 2014;3(10):1116-1124.